A61K 31/426
1,3-thiazoles
Official title: 1,3-Thiazoles
A61K31/426 (1,3-thiazoles) appears on 1,684 US grants and 3,172 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,684
- Published applications
- 3,172
- Assignees
- 1,262
- Inventors
- 6,400
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 2 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 4 | 0 |
| 1996 | 12 | 0 |
| 1997 | 18 | 0 |
| 1998 | 21 | 0 |
| 1999 | 31 | 0 |
| 2000 | 24 | 0 |
| 2001 | 35 | 13 |
| 2002 | 27 | 73 |
| 2003 | 36 | 95 |
| 2004 | 30 | 92 |
| 2005 | 28 | 121 |
| 2006 | 33 | 110 |
| 2007 | 30 | 136 |
| 2008 | 27 | 114 |
| 2009 | 29 | 100 |
| 2010 | 38 | 101 |
| 2011 | 45 | 107 |
| 2012 | 74 | 102 |
| 2013 | 72 | 154 |
| 2014 | 81 | 158 |
| 2015 | 110 | 146 |
| 2016 | 96 | 151 |
| 2017 | 95 | 146 |
| 2018 | 89 | 153 |
| 2019 | 102 | 139 |
| 2020 | 91 | 137 |
| 2021 | 88 | 143 |
| 2022 | 80 | 175 |
| 2023 | 63 | 142 |
| 2024 | 61 | 132 |
| 2025 | 61 | 126 |
| 2026 | 50 | 106 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Injectable formulations in a method for treating pain6 Oct 2026US 12,751,943 B2Pelthos Therapeutics Inc.
- Small molecule inhibitors of viral replication6 Oct 2026US 12,751,963 B2The Trustees of Princeton University
- Methods for the treatment of conditions related to hydrogen sulfide22 Sep 2026US 12,740,968 B2Regents of the University of Minnesota
- Polymorphs of Ponesimod15 Sep 2026US 12,735,391 B2Tapi Czech Industries S.R.O
- Methods of treating multiple sclerosis8 Sep 2026US 12,728,116 B2Vanda Pharmaceuticals Inc.
- Polymer-based therapeutics for inductive browning of fat8 Oct 2026US 2026/0306643 A1Purdue Research Foundation
- Dosage regime of crinecerfont for treating congenital adrenal hyperplasia in a pediatric subject1 Oct 2026US 2026/0294876 A1Neurocrine Biosciences, Inc.
- Therapeutic compounds1 Oct 2026US 2026/0297016 A1Regents of the University of Minnesota
- Biarylamide derivatives and their use as pkmyt1 inhibitors1 Oct 2026US 2026/0297042 A1Cancer Research Technology Limited
- Hdac1/2 selective inhibitor and use thereof1 Oct 2026US 2026/0297110 A1Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Most cited
By later US patents
- Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension648US 5,674,533 ARecordati S.A., Chemical and Pharmaceutical Company · 1997
- Anti-angiogenic compositions and methods of use242US 6,544,544 B2Angiotech Pharmaceuticals, Inc. · 2003
- Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals233US 6,303,661 B1Probiodrug AG · 2001
- Albumin fusion proteins comprising GLP-1 polypeptides198US 7,141,547 B2Human Genome Sciences, Inc. · 2006
- Compositions and methods for treating surgical adhesions160US 6,689,803 B2Angiotech Pharmaceuticals, Inc. · 2004